Cell and Gene Therapy CRO Market (3rd Edition): Distribution by Area of Expertise (Cell Therapy and Gene Therapy), Scale of Operation (Clinical, Preclinical and Discovery), Therapeutic Area (Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Infectious Diseases, Metabolic Disorders, Autoimmune Disorders, Blood Disorders, Rare / Genetic Disorders, Ophthalmological Disorders, and Other disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2022

  • Pages
    330

  • View Count
    16211

Example Insights

Cell-and-Gene-Therapy-CROs-Market-Context-thumb Cell-and-Gene-Therapy-CROs-Market-Landscape-thumb Cell-and-Gene-Therapy-CROs-Market-Distribution-by-Company-thumb Cell-and-Gene-Therapy-CROs-Market-Clinical-Research-thumb
Cell-and-Gene-Therapy-CROs-Market-Benchmark-Analysis-thumb Cell-and-Gene-Therapy-CROs-Market-Partnership-and-Collaborations -thumb Cell-and-Gene-Therapy-CROs-Market-Mergers-and-Acquisitions-thumb Cell-and-Gene-Therapy-CROs-Market-Developers-thumb
Cell-and-Gene-Therapy-CROs-Market-Key-Acquisiton-Targerts-thumb Cell-and-Gene-Therapy-CROs-Market-Distribution-By-Key-Parameters-thumb Cell-and-Gene-Therapy-CROs-Market-Distribution-By-Scale-of-Operation-thumb  

Overview

Cell and gene therapy candidates have been demonstrated to have the potential to treat complex and rare diseases, including indications, for which no effective treatment is currently available. In this context, it is important to mention that, in case of cell therapy, human cells are transplanted to repair or replace the damaged cells / tissues, thereby, enabling their treatment through alteration or restoration of certain sets of cells. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells). On the other hand, gene therapy aims to correct the underlying genetic problem to ensure the treatment, as well as prevention of diseases, by replacing, inactivating or introducing genes into cells, either inside or outside of the body. It is worth highlighting that some therapeutic interventions can be considered both cell and gene therapies. The mechanism of action of such therapies usually involves alteration of genes in specific types of cells and then, their insertion into the patient body.

How is the research and development (R&D) activity evolving in the cell and gene therapy industry?

At present, cell and gene therapy industry is one of the fastest growing therapeutic segments, already having contributed to some of the most significant disruptions in the biopharmaceutical domain. Till date, 23 cell and gene therapies have been approved by the Food and Drug Administration (FDA) in the US, while more than 1,000 IND applications have been filed for candidates being evaluated in ongoing clinical studies. This further indicates a remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. 

What is the need for contract research organizations (CROs) in the cell and gene therapy domain?

At present, only a few therapeutic developers have the required technical expertise to carry out in-house clinical research. This can be attributed to the high costs associated with acquiring the necessary infrastructure and capabilities to carry out research. Other key concerns shared by contemporary innovators include limited availability of expertise, high rate of attrition of pipeline drugs / therapies and prolonged development timelines. The aforementioned challenges are believed to be the key factors for driving the outsourcing of research operations to a cell and gene therapy CRO, which claim to be well-aware of the nuances of advanced therapy medicinal products (ATMPs) design and development, as well as cell and gene therapy manufacturing process. 

What are the current opportunities in the cell and gene therapy CRO market?

Due to the upsurge in the research and development related to genetic engineering, there has been a considerable increase in the development of cell and gene therapies. Consequently, there has been a parallel rise in outsourcing of services as more clinical studies are anticipated to start. Specifically, cell and gene therapy companies have made significant investments to support the development / adoption of advanced tools, technologies and platforms, to generate more robust and evidence based clinical data, which is required for gaining the marketing authorizations across different geographies. For instance, in 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. Further, CROs are believed to play a significant role in the successful approval of these drugs in a highly evolving regulatory environment. Since 2005, over 40 CROs have been established in this domain. It is worth mentioning that cell and gene therapy CROs are bolstering their existing capabilities to offer a wide range of services to their clients. 

What are the recent developments and expected trends in the cell and gene therapy industry?

Presently, more than 3,570 cell and gene therapies are being evaluated across various stages of clinical development for a myriad of disease indications. Given that the demand for cell and gene therapies is indubitably rising, more than 53% mergers and acquisitions have been undertaken by service providers in this market, since 2015. Considering the prevalent trends and projected opportunity associated with the overall cell and gene therapies market, we believe that the cell and gene therapy CRO market is likely to witness a consistent growth, till 2035.

What are the key challenges faced by cell and gene therapy CROs?

One of the key challenges faced by cell and gene therapy CROs is the lack of understanding of the standard operating procedures (SOPs). In addition, various regulatory guidelines render therapies subject to rigorous quality assessments, thereby, making it difficult for firms with limited finances to undertake research initiatives.

What are the key value drivers in the cell and gene therapy market?

A significant rise in healthcare expenditure, R&D spending and booming research have emerged as key value drivers in the cell and gene therapy domain. 

How is the revenue generation potential associated with cell and gene therapy CROs likely to evolve in the coming years?

The cell and gene therapy CROs market is likely to witness a substantial growth in the coming years. It is worth mentioning that, presently in terms of area of expertise, the market is likely to be driven by cell therapies, and this trend is unlikely to change in the foreseen future as well. Further, based on scale of operation, majority of the revenue share is likely to be associated with clinical operations. Specifically, in terms of global regions, the cell and gene therapy market in Asia-Pacific is likely to grow at a relatively faster pace (21%), in the long term. 

Who are the key players engaged in the cell and gene therapy CROs market?

The key players engaged in this domain (which have also been capture in this report) include Altasciences, Allucent, Accelera Charles River Laboratories, Creative Biolabs, CMIC, Evotec, ICON, IQVIA, Labcorp, Medpace, PPD, Precision For Medicine, QPS and Syneos Health.

Scope of the Report

The “Cell and Gene Therapy CROs Market (3rd Edition), 2022-2035: Distribution by Area of Expertise (Cell Therapy and Gene Therapy), Scale of Operation (Clinical, Preclinical and Discovery), Therapeutic Area (Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Infectious Diseases, Metabolic Disorders, Autoimmune Disorders, Blood Disorders, Rare / Genetic Disorders, Ophthalmological Disorders, and Other disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa)” report features an extensive study of the current market landscape and future potential of the cell and gene therapy CROs market, over the next decade.

The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features: 

  • A detailed overview of the overall market landscape of the cell and gene therapy CROs, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, area of expertise (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operation (discovery, preclinical, clinical and commercial) and types of services offered, including [A] preclinical services (bioanalytical services, in-vivo studies, pharmacokinetic and ADME services, preclinical safety studies, toxicology studies and other preclinical services), [B] clinical services (clinical research monitoring, clinical trial management/ clinical project management, data management, safety and pharmacovigilance, and other clinical services), [C] regulatory services (GAP analysis, IND preparation, legal representation and technical dossier submission) and [D] general support services (biostatistics, consulting, post-market assessment, re-imbursement and training).
  • A detailed analysis on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies. In addition, it includes information on various factors that drive developers towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.  
  • Elaborate profiles of key industry players (very large and large companies) based in North America, Europe and Asia-Pacific that offer contract research services for both cell and gene therapies across both preclinical and clinical scales of operation. Each profile features a brief overview of the company, along with details related to its cell and gene therapies-related service portfolio, recent developments, and an informed future outlook.
  • A benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to gain a competitive edge in the industry.  
  • An analysis of the recent collaborations within the cell and gene therapy contract research industry, based on several relevant parameters, such as year of partnership, type of partnership, area of expertise, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2022, based on several parameters, such as year, type of agreement, area of expertise, geographical location of the companies and key value drivers.
  • A detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • A list of over 310 cell therapy developers that are anticipated to partner with cell therapy CROs. These players have been shortlisted based on several relevant parameters, such as developer strength (based on company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), and availability of other cell therapy capabilities.
  • An in-depth analysis of nearly 235 gene therapy developers that are anticipated to partner with gene therapy CROs and have been shortlisted on the basis of several relevant parameters, such as developer strength (based on company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various cell and gene therapies, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), therapeutic area and key geographical regions.
  • A detailed analysis of the total cost of ownership for large / very large cell and gene therapy contract research organizations. It features an informed estimate of direct and indirect expenses taking into consideration various relevant parameters, over a span of 20 years.
  • A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.

One of the key objectives of this report was to evaluate the current opportunity and the future growth potential of the cell and gene therapy CROs market over the coming years. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across important parameters, such as [A] area of expertise (cell therapy and gene therapy), [B] scale of operation (clinical, preclinical and discovery), [C] therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, infectious diseases, metabolic disorders, autoimmune disorders, blood disorders, rare / genetic disorders, ophthalmological disorders, and other disorders), and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).  

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION 
3.1. Chapter Overview 
3.2. Overview of Contract Research Organizations (CROs) 
3.2.1. Evolution of CROs 
3.2.2. Modern CROs and Prevalent Outsourcing Trends 
3.3. Type of Services Offered by CROs 
3.4. Classification of CROs 
3.5. Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs)
3.6. Advantages of Outsourcing Operations to CROs 
3.7. Risks Associated with Outsourcing to CROs 
3.8. Future Perspectives 

4. GUIDE TO OUTSOURCING
4.1. Chapter Overview 
4.2. Outsourcing Cell and Gene Therapy Research  
4.3. Guiding Models of Outsourcing 
4.3.1. Transactional Outsourcing Model 
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Models 
4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach
4.5. Selecting a CRO Partner
4.5.1 Key Considerations while Outsourcing Cell and Gene Therapy-related Operations
4.6. Role of CROs in Drug Development 
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services
4.7. Concluding Remarks

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cell and Gene Therapy CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Scale of Operation
5.3.5. Analysis by Area of Expertise 
5.3.6. Analysis by Number of Preclinical Services
5.3.7. Analysis by Type of Preclinical Service(s) Offered
5.3.8. Analysis by Number of Clinical Services 
5.3.9. Analysis by Type of Clinical Service(s) Offered
5.3.10. Analysis by Type of Regulatory Service(s) Offered
5.3.11. Analysis by Type of General Support Service(s) Offered

6. COMPANY PROFILES
6.1. Chapter Overview 
6.2. Players based in North America
6.2.1. Altasciences
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook

6.2.2. Allucent (Formerly Known as CATO SMS) 
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook

6.2.3. Charles River Laboratories
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Service Portfolio
6.2.3.4. Recent Developments and Future Outlook

6.2.4. Creative Biolabs
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Recent Developments and Future Outlook

6.2.5. IQVIA
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Service Portfolio
6.2.5.4. Recent Developments and Future Outlook

6.2.6. Medpace 
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Service Portfolio
6.2.6.4. Recent Developments and Future Outlook

6.2.7. PPD
6.2.7.1. Company Overview
6.2.7.2. Financial Information
6.2.7.3. Service Portfolio
6.2.7.4. Recent Developments and Future Outlook

6.2.8. Precision for Medicine
6.2.8.1. Company Overview
6.2.8.2. Service Portfolio
6.2.8.3. Recent Developments and Future Outlook

6.2.9. QPS
6.2.9.1. Company Overview
6.2.9.2. Service Portfolio
6.2.9.3. Recent Developments and Future Outlook

6.3. Players based in Europe 
6.3.1. Accelera 
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook

6.3.2. Evotec
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Service Portfolio
6.3.2.4. Recent Developments and Future Outlook

6.3.3. ICON
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook

6.3.4. Syneos Health 
6.3.4.1. Company Overview
6.3.4.2. Financial Information
6.3.4.3. Service Portfolio
6.3.4.4. Recent Developments and Future Outlook

6.4. Players based in Asia-Pacific
6.4.1.1. CMIC Group
6.4.1.2. Company Overview
6.4.1.3. Financial Information
6.4.1.4. Service Portfolio
6.4.1.5. Recent Developments and Future Outlook

6.4.2. Labcorp
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Service Portfolio
6.4.2.4. Recent Developments and Future Outlook

7. COMPETITIVE BENCHMARKING
7.1. Chapter Overview
7.2. Assumptions and Key Methodology
7.3. Competitive Benchmarking by Region
7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
7.3.7. Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific and RoW (Peer Group VII)
7.4. Concluding Remarks

8. PARTNERSHIPS AND COLLABORATIONS 
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell and Gene Therapy CROs: Partnerships and Collaborations 
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Partnership and Company Size
8.3.5. Analysis by Area of Expertise
8.3.6. Analysis by Year of Partnership and Area of Expertise
8.3.7. Analysis by Type of Partnership and Area of Expertise
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Analysis by Region
8.3.9.1. Intracontinental and Intercontinental Deals
8.3.9.2. Local and International Deals

9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Cell and Gene Therapy CROs: Mergers and Acquisitions
9.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
9.3.2. Analysis by Type of Agreement
9.3.3. Analysis by Region
9.3.3.1. Mergers and Acquisitions: Continent-wise Distribution
9.3.3.2. Mergers and Acquisitions: Country-wise Distribution
9.3.4. Most Active Acquirers: Analysis by Number of Acquisitions
9.3.5. Analysis by Key Value Drivers
9.3.6. Analysis by Year of Acquisition and Key Value Drivers
9.3.7. Key Acquisitions: Deal Multiples

10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scoring Criteria and Key Assumptions
10.3. Scope and Methodology
10.4. Potential Strategic Acquisition Targets Amongst Small Players
10.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players

11. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs
11.1. Chapter Overview
11.2. Scoring Criteria and Key Assumptions
11.3. Scope and Methodology
11.4. Key Potential Strategic Partners for Cell Therapy CROs
11.4.1. Likely Partner Opportunities for Dendritic Cell Therapy CROs
11.4.2. Likely Partner Opportunities for NK Cell Therapy CROs
11.4.3. Likely Partner Opportunities for Stem Cell Therapy CROs
11.4.4. Likely Partner Opportunities for T-Cell Therapy CROs

12. LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs
12.1. Chapter Overview
12.2. Scoring Criteria and Key Assumptions
12.3. Scope and Methodology
12.4. Key Potential Strategic Partners for Gene Therapy CROs 
12.4.1. Likely Partner Opportunities in North America
12.4.2. Likely Partner Opportunities in Europe
12.4.3. Likely Partner Opportunities in Asia-Pacific and RoW

13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapies: Analysis by Number of Clinical Trials
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Status
13.3.3. Analysis by Trial Phase
13.3.4. Analysis by Therapeutic Area
13.3.5. Analysis by Type of Sponsor
13.3.6. Analysis by Geography
13.3.7. Analysis by Trial Registration Year and Geography
13.3.8. Analysis by Trial Status and Geography
13.3.9. Analysis by Trial Phase and Geography
13.4. Cell Therapies: Analysis by Enrolled Patient Population
13.4.1. Analysis by Trial Registration Year
13.4.2. Analysis by Trial Status
13.4.3. Analysis by Trial Phase
13.4.4. Analysis by Location of Trial Site
13.4.5. Analysis by Trial Status and Location of Trial Site
13.4.6. Analysis by Trial Status, Trial Phase and Location of Trial Site
13.5. Gene Therapies: Analysis by Number of Clinical Trials
13.5.1. Analysis by Trial Registration Year
13.5.2. Analysis by Trial Status
13.5.3. Analysis by Trial Phase
13.5.4. Analysis by Therapeutic Area
13.5.5. Analysis by Type of Sponsor
13.5.6. Analysis by Location of Trial Site
13.5.7. Analysis by Geography
13.5.8. Analysis by Trial Registration Year and Geography
13.5.9. Analysis by Trial Status and Geography
13.5.10. Analysis by Trial Status, Trial Phase and Geography
13.5.11. Analysis by Therapeutic Area and Geography
13.6. Gene Therapies: Analysis by Enrolled Patient Population
13.6.1. Analysis by Trial Registration Year
13.6.2. Analysis by Trial Status
13.6.3. Analysis by Trial Phase
13.6.4. Analysis by Therapeutic Area
13.6.5. Analysis by Location of Trial Site
13.6.6. Analysis by Trial Status and Location of Trial Site
13.6.7. Analysis by Trial Status, Trial Phase and Location of Trial Site
13.6.8. Analysis by Therapeutic Area and Location of Trial Site

14. TOTAL COST OF OWNERSHIP FOR CELL AND GENE THERAPY CONTRACT RESEARCH ORGANIZATIONS
14.1 Chapter Overview
14.2. Key Parameters
14.3. Assumptions and Methodology
14.4. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2022-2042
14.4.1. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX and OPEX, 2023-2042
14.4.2. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX, 2023-2042
14.4.3. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by OPEX, 2023-2042

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology 

15.3. Global Cell and Gene Therapy CROs Market, 2022-2035
15.3.1. Cell and Gene Therapy CROs Market: Analysis by Area of Expertise
15.3.1.1. Cell Therapy CROs Market, 2022-2035
15.3.1.2. Gene Therapy CROs Market, 2022-2035

15.3.2. Cell and Gene Therapy CROs Market: Analysis by Scale of Operation
15.3.2.1. Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035
15.3.2.2. Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035
15.3.2.3. Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035

15.3.3. Cell and Gene Therapy CROs Market: Analysis by Therapeutic Area, 2022-2035
15.3.3.1. Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035
15.3.3.2. Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035
15.3.3.3. Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035
15.3.3.4. Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035
15.3.3.5. Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035
15.3.3.6. Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035
15.3.3.7. Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035
15.3.3.8. Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035
15.3.3.9. Cell and Gene Therapy CROs Market for Ophthalmological Disorders, 2022-2035
15.3.3.10. Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035

15.3.4. Cell and Gene Therapy CROs Market: Analysis by Geography, 2022-2035
15.3.4.1. Cell and Gene Therapy CROs Market in North America, 2022-2035
15.3.4.2. Cell and Gene Therapy CROs Market in Europe, 2022-2035
15.3.4.3. Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035
15.3.4.4. Cell and Gene Therapy CROs Market in Latin America, 2022-2035
15.3.4.5. Cell and Gene Therapy CROs Market in MENA, 2022-2035

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors

17. CONCLUSION
17.1. Chapter Overview

18. INTERVIEW AND SURVEY TRANSCRIPTS
18.1. Chapter Overview
18.2. CATO SMS
18.2.1. Company Snapshot
18.2.2. Survey Transcript: Jessica Bliven, Director, Marketing and Sales

18.3. Changhai Hospital, Second Military Medical University
18.3.1. University Snapshot
18.3.2. Survey Transcript: Xian-Bao Zhan, Professor of Medicine, Director,Department of Oncology

18.4. University of Colorado
18.4.1. University Snapshot
18.4.2. Survey Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Mergers and Acquisitions
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Stages of the Drug Development Process
Figure 3.2 Services Offered by CROs
Figure 3.3 Advantages of Outsourcing Operations to CROs
Figure 3.4 Risks Associated with Outsourcing Operations to CROs
Figure 3.5 Classification of ATMPs
Figure 3.6 Types of Cells Incorporated in Cell Therapy Medicinal Products (CTMPs)
Figure 4.1 Guiding Models of Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance / Outcome-based Business Model
Figure 4.4 Key Considerations while Selecting a CRO Partner
Figure 4.5 Role of CROs across Different Phases of Drug Development
Figure 5.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
Figure 5.2 Cell and Gene Therapy CROs: Distribution by Company Size
Figure 5.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size, and Location of Headquarters
Figure 5.6 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Figure 5.7 Cell and Gene Therapy CROs: Distribution by Area of Expertise
Figure 5.8 Cell and Gene Therapy CROs: Distribution by Scale of Operation and Area of Expertise
Figure 5.9 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
Figure 5.10 Cell and Gene Therapy CROs: Distribution by Number of Preclinical Services
Figure 5.11 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Service(s) Offered
Figure 5.12 Cell and Gene Therapy CROs: Distribution by Number of Clinical Services
Figure 5.13 Cell and Gene Therapy CROs: Distribution by Type of Clinical Service(s) Offered
Figure 5.14 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Service(s) Offered
Figure 5.15 Cell and Gene Therapy CROs: Distribution by Type of General Service(s) Offered
Figure 6.1 Altasciences: Service Portfolio
Figure 6.2 Allucent (Formerly known as CATO SMS): Service Portfolio
Figure 6.3 Charles River Laboratories: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Figure 6.4 Charles River Laboratories: Service Portfolio
Figure 6.5 Creative Biolabs: Service Portfolio for CAR-T Therapy Development
Figure 6.6 Creative Biolabs: Service Portfolio for TCR Therapy Development
Figure 6.7 IQVIA: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Figure 6.8 IQVIA: Service Portfolio
Figure 6.9 Medpace: Annual Revenues, FY 2017-Q1 2022 (USD Million)
Figure 6.10 Medpace: Service Portfolio
Figure 6.11 Medpace: Regulatory Affair Capabilities
Figure 6.12 PPD: Annual Revenues, FY 2017-9M 2021 (USD Billion)
Figure 6.13 PPD: Service Portfolio
Figure 6.14 Precision for Medicine: Service Portfolio
Figure 6.15 QPS: Service Portfolio
Figure 6.16 Accelera: Service Portfolio
Figure 6.17 Evotec: Annual Revenues, FY 2017-Q1 2022 (EUR Million)
Figure 6.18 Evotec: Service Portfolio
Figure 6.19 ICON: Service Portfolio
Figure 6.20 Syneos Health: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Figure 6.21 Syneos Health: Service Portfolio
Figure 6.22 CMIC Group: Annual Revenues, 2017-H1 2022 (JPY Billion)
Figure 6.23 CMIC Group: Service Portfolio
Figure 6.24 Labcorp: Annual Revenues, FY 2017- Q1 2022 (USD Billion)
Figure 6.25 Labcorp: Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution by Location of Headquarters and Company Size
Figure 7.2 Competitive Benchmarking: Small Players based in North America (Peer Group I)
Figure 7.3 Competitive Benchmarking: Mid-Sized Players based in North America (Peer Group II)
Figure 7.4 Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
Figure 7.5 Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
Figure 7.6 Competitive Benchmarking: Mid-Sized Players based in Europe (Peer Group V)
Figure 7.7 Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
Figure 7.8 Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific and RoW (Peer Group VII)
Figure 7.9 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 8.5 Partnerships and Collaborations: Distribution by Area of Expertise
Figure 8.6 Partnerships and Collaborations: Distribution by Year of Partnership and Area of Expertise
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Expertise
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 8.10 Partnerships and Collaborations: Local and International Deals
Figure 9.1 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2022
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 9.3 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Figure 9.4 Mergers and Acquisitions: Distribution by Region (Country-wise)
Figure 9.5 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 9.6 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 9.7 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 9.8 Mergers and Acquisitions: Distribution by Deal Multiples Based on Revenues
Figure 13.1 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Figure 13.2 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Figure 13.3 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Figure 13.4 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area
Figure 13.5 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Figure 13.6 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Number of Registered Trials
Figure 13.7 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Registration Year
Figure 13.8 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Status
Figure 13.9 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Phase
Figure 13.10 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 13.11 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status
Figure 13.12 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.13 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population
Figure 13.14 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
Figure 13.15 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Phase
Figure 13.16 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Figure 13.17 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Figure 13.18 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Figure 13.19 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
Figure 13.20 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Figure 13.21 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
Figure 13.22 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Number of Registered Trials
Figure 13.23 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Registration Year
Figure 13.24 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status
Figure 13.25 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status and Trial Phase
Figure 13.26 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Therapeutic Area
Figure 13.27 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 13.28 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status
Figure 13.29 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.30 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Therapeutic Area
Figure 13.31 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population
Figure 13.32 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
Figure 13.33 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status and Trial Phase
Figure 13.34 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Figure 14.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 14.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 14.3 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2022-2042 (USD Million)
Figure 14.4 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
Figure 14.5 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023: Distribution by CAPEX (USD Million)
Figure 14.6 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023-2042: Distribution by OPEX (USD Million)
Figure 15.1 Global Cell and Gene Therapy CROs Market, 2022-2035 (USD Million)
Figure 15.2 Cell and Gene Therapy CROs Market: Distribution by Area of Expertise
Figure 15.3 Cell Therapy CROs Market, 2022-2035 (USD Million)
Figure 15.4 Gene Therapy CROs Market, 2022-2035 (USD Million)
Figure 15.5 Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
Figure 15.6 Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035 (USD Million)
Figure 15.7 Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035 (USD Million)
Figure 15.8 Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035 (USD Million)
Figure 15.9 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
Figure 15.10 Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035 (USD Million)
Figure 15.11 Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035 (USD Million)
Figure 15.12 Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Figure 15.13 Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035 (USD Million)
Figure 15.14 Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035 (USD Million)
Figure 15.15 Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035 (USD Million)
Figure 15.16 Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035 (USD Million)
Figure 15.17 Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035 (USD Million)
Figure 15.18 Cell and Gene Therapy CROs Market for Ophthalmological Disorders, 2022-2035 (USD Million)
Figure 15.19 Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035 (USD Million)
Figure 15.20 Cell and Gene Therapy CROs Market: Distribution by Geography, 2022 and 2035
Figure 15.21 Cell and Gene Therapy CROs Market in North America, 2022-2035 (USD Million)
Figure 15.22 Cell and Gene Therapy CROs Market in Europe, 2022-2035 (USD Million)
Figure 15.23 Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 15.24 Cell and Gene Therapy CROs Market in Latin America, 2022-2035 (USD Million)
Figure 15.25 Cell and Gene Therapy CROs Market in MENA, 2022-2035 (USD Million)
Figure 16.1 Cell and Gene Therapy CROs SWOT Analysis: Overview
Figure 17.1 Concluding Remarks: Overall Market Landscape
Figure 17.2 Concluding Remarks: Partnerships and Collaborations
Figure 17.3 Concluding Remarks: Mergers and Acquisitions
Figure 17.4 Concluding Remarks: Clinical Trial Analysis
Figure 17.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 List of Approved ATMP Products
Table 4.1 Attributes of Transactional Outsourcing-based Business Model
Table 5.1 List of Cell and Gene Therapy CROs
Table 5.2 Cell and Gene Therapy CROs: Information on Type of Preclinical Service(s) Offered
Table 5.3 Cell and Gene Therapy CROs: Information on Type of Clinical Service(s) Offered
Table 5.4 Cell and Gene Therapy CROs: Information on Type of Regulatory Service(s) Offered
Table 5.5 Cell and Gene Therapy CROs: Information on Type of General Service(s) Offered
Table 6.1 Altasciences: Company Overview
Table 6.2 Altasciences: Recent Developments and Future Outlook
Table 6.3 Allucent (Formerly known as CATO SMS): Company Overview
Table 6.4 Allucent (Formally Known as CATO SMS): Recent Developments and Future Outlook
Table 6.5 Charles River Laboratories: Company Overview
Table 6.6 Charles River Laboratories: Recent Developments and Future Outlook
Table 6.7 Creative Biolabs: Company Overview
Table 6.8 IQVIA: Company Overview
Table 6.9 Medpace: Company Overview
Table 6.10 PPD: Company Overview
Table 6.11 PPD: Recent Developments and Future Outlook
Table 6.12 Precision for Medicine: Company Overview
Table 6.13 Precision for Medicine: Recent Developments and Future Outlook
Table 6.14 QPS: Company Overview
Table 6.15 Accelera: Company Overview
Table 6.16 Evotec: Company Overview
Table 6.17 ICON: Company Overview
Table 6.18 ICON: Recent Developments and Future Outlook
Table 6.19 Syneos Health: Company Overview
Table 6.20 Syneos Health: Recent Developments and Future Outlook
Table 6.21 CMIC Group: Company Overview
Table 6.22 CMIC Group: Recent Developments and Future Outlook
Table 6.23 Labcorp: Company Overview
Table 6.24 Labcorp: Recent Developments and Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 Cell and Gene Therapy CROs: List of Partnerships and Collaborations, 2015-2022
Table 9.1 Cell and Gene Therapy CROs: List of Mergers and Acquisitions, 2015-2022
Table 9.2 Cell and Gene Therapy CROs Mergers and Acquisitions: Information on Key Value Drivers and Area of Expertise, 2015-2022
Table 9.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2022
Table 10.1 Potential Strategic Acquisition Targets Amongst Small Players
Table 10.2 Potential Strategic Acquisition Targets Amongst Mid-sized Players
Table 11.1 Likely Partners for Dendritic Cell Therapy CROs
Table 11.2 Likely Partners for NK Cell Therapy CROs
Table 11.3 Likely Partners for Stem Cell Therapy CROs
Table 11.4 Likely Partners for T-Cell Therapy CROs
Table 12.1 Likely Partner Opportunities in North America
Table 12.2 Likely Partner Opportunities in Europe
Table 12.3 Likely Partner Opportunities in Asia-Pacific and RoW
Table 13.1 Clinical Trial Analysis: Emerging Molecules
Table 13.2 Clinical Trial Analysis: Most Important Trials
Table 19.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
Table 19.2 Cell and Gene Therapy CROs: Distribution by Company Size
Table 19.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region-wise)
Table 19.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country-wise)
Table 19.5 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 19.6 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Table 19.7 Cell and Gene Therapy CROs: Distribution by Area of Expertise
Table 19.8 Cell and Gene Therapy CROs: Distribution by Scale of Operation and Area of Expertise
Table 19.9 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
Table 19.10 Cell and Gene Therapy CROs: Distribution by Number of Preclinical Services
Table 19.11 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Service(s) Offered
Table 19.12 Cell and Gene Therapy CROs: Distribution by Number of Clinical Services
Table 19.13 Cell and Gene Therapy CROs: Distribution by Type of Clinical Service(s) Offered
Table 19.14 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Service(s) Offered
Table 19.15 Cell and Gene Therapy CROs: Distribution by Type of General Service(s) Offered
Table 19.16 Charles River Laboratories: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 19.17 IQVIA: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 19.18 Medpace: Annual Revenues, FY 2017-Q1 2022 (USD Million)
Table 19.19 PPD: Annual Revenues, FY 2017-9M 2021 (USD Billion)
Table 19.20 Evotec: Annual Revenues, FY 2017-Q1 2022 (EUR Million)
Table 19.21 Syneos Health: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 19.22 CMIC Group: Annual Revenues, 2017-H1 2022 (JPY Billion)
Table 19.23 Labcorp: Annual Revenues, FY 2017- Q1 2022 (USD Billion)
Table 19.24 Benchmark Analysis: Distribution by Location of Headquarters and Company Size
Table 19.25 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Table 19.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.27 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 19.28 Partnerships and Collaborations: Distribution by Area of Expertise
Table 19.29 Partnerships and Collaborations: Distribution by Year of Partnership and Area of Expertise
Table 19.30 Most Active Players: Distribution by Number of Partnerships
Table 19.31 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Table 19.32 Partnerships and Collaborations: Local and International Deals
Table 19.33 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2022
Table 19.34 Mergers and Acquisitions: Distribution by Type of Agreement
Table 19.35 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Table 19.36 Mergers and Acquisitions: Distribution by Region (Country-wise)
Table 19.37 Most Active Acquirers: Distribution by Number of Acquisitions
Table 19.38 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 19.39 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 19.40 Mergers and Acquisitions: Deal Multiples Based on Revenues
Table 19.41 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Table 19.42 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Table 19.43 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Table 19.44 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area
Table 19.45 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Table 19.46 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Number of Registered Trials
Table 19.47 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Registration Year
Table 19.48 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Status
Table 19.49 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Trial Phase
Table 19.50 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 19.51 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status
Table 19.52 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
Table 19.53 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population
Table 19.54 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
Table 19.55 Clinical Trial Analysis for Cell Therapies: Geographical Distribution of Enrolled Patient Population by Trial Phase
Table 19.56 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Table 19.57 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Table 19.58 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Table 19.59 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
Table 19.60 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Table 19.61 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
Table 19.62 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Number of Registered Trials
Table 19.63 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Registration Year
Table 19.64 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status
Table 19.65 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Trial Status and Trial Phase
Table 19.66 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Therapeutic Area
Table 19.67 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 19.68 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status
Table 19.69 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
Table 19.70 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Therapeutic Area
Table 19.71 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population
Table 19.72 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status
Table 19.73 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Trial Status and Trial Phase
Table 19.74 Clinical Trial Analysis for Gene Therapies: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Table 19.75 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2022-2042 (USD Million)
Table 19.76 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Distribution by CAPEX and OPEX, 2023 and 2042 (USD Million)
Table 19.77 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023: Distribution by CAPEX (USD Million)
Table 19.78 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, 2023-2042: Distribution by OPEX (USD Million)
Table 19.79 Global Cell and Gene Therapy CROs Market 2022-2035 (USD Million)
Table 19.80 Cell and Gene Therapy CROs Market: Distribution by Area of Expertise
Table 19.81 Cell Therapy CROs Market, 2022-2035 (USD Million)
Table 19.82 Gene Therapy CROs Market, 2022-2035 (USD Million)
Table 19.83 Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
Table 19.84 Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035 (USD Million)
Table 19.85 Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035 (USD Million)
Table 19.86 Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035 (USD Million)
Table 19.87 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
Table 19.88 Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035 (USD Million)
Table 19.89 Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035 (USD Million)
Table 19.90 Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Table 19.91 Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035 (USD Million)
Table 19.92 Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035 (USD Million)
Table 19.93 Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035 (USD Million)
Table 19.94 Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035 (USD Million)
Table 19.95 Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035 (USD Million)
Table 19.96 Cell and Gene Therapy CROs Market for Ophthalmological Disorders, 2022-2035 (USD Million)
Table 19.97 Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035
Table 19.98 Cell and Gene Therapy CROs Market: Distribution by Geography, 2022 and 2035 (USD Million)
Table 19.99 Cell and Gene Therapy CROs Market in North America, 2022-2035 (USD Million)
Table 19.100 Cell and Gene Therapy CROs Market in Europe, 2022-2035 (USD Million)
Table 19.101 Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035 (USD Million)
Table 19.102 Cell and Gene Therapy CROs Market in Latin America, 2022-2035 (USD Million)
Table 19.103 Cell and Gene Therapy CROs Market in MENA, 2022-2035 (USD Million)

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com